DNAprint Genomics (DNAG)

[ann441j]

Dr. Fru:

I am also reminding you:

"Forming such a close alliance with a US company is a significant milestone for Biofrontera. It provides us with substantial resources we need to move our products ahead in clinical development, and to establish the key clinical milestones which will form the basis of the future value of Biofrontera”, commented Hermann Lübbert. “We are excited by the recent progress in developing our lead product BF-Derm1 for the treatment of severe chronic Urticaria, and the proceeds of this investment should enable us to bring this and other promising products to the market within the next three years."

Ann